Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men

被引:11
|
作者
Meikle, AW
Matthias, D
Hoffman, AR
机构
[1] Univ Utah, Sch Med, Dept Med, Div Endocrinol, Salt Lake City, UT 84108 USA
[2] ARUP Labs, Salt Lake City, UT USA
[3] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[4] VA Palo Alto Care Syst, Palo Alto, CA USA
[5] Stanford Univ, Palo Alto, CA 94304 USA
关键词
hypogonadism; testosterone; transdermal gel; pharmacokinetics;
D O I
10.1111/j.1464-410X.2003.04750.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine the regimen that would most effectively maintain serum testosterone concentrations in treated hypogonadal men within the normal reference range of 3-11.4 mug/L. PATIENTS AND METHODS Eighteen men aged 24-69 years with either primary or secondary hypogonadism participated in and 16 completed a randomized, six-treatment regimen, three-period (phase), three-way matrix-type crossover study. A 1% and 2% testosterone gel (CP601, Cellegy Pharmaceuticals, Inc., San Francisco, USA) was administered either once or twice daily transdermally at different body sites to determine optimal dosing, application sites, and its pharmacokinetics and tolerability in hypogonadal men. Treatments A-F included 1 g of 1% and 2% gel that was equivalent to 10 or 20 mg of testosterone, applied once or twice daily to the skin of either the thigh or the upper arm. Six men also participated in a study of 3 g of 2% gel that was equivalent to 60 mg of testosterone applied once daily, half on each thigh. Pharmacokinetic variables were calculated for testosterone for each man in each treatment period and the results analysed by ANOVA. RESULTS In general the higher dose regimens produced higher serum concentrations of testosterone; the 3 g/2% dose was most successful in maintaining serum testosterone within the normal reference range. The average testosterone concentration (C-avg) was 6.52 mug/L and all men had a C-avg of > 3.0 mug/L. The prediction of all men achieving a C-avg of > 3.0 mug/L was 96%. The mean minimum concentration (C-min) was 3.83 mug/L and half the patients had a C-min of > 3.0 mug/L. Most men had serum testosterone levels within the normal reference range throughout the 24 h, and the treatment was well tolerated. CONCLUSIONS The 3 g/2% dose applied to the skin daily resulted in serum testosterone in the normal reference range in most hypogonadal men. Dose adjustments to either a lower or higher dose should shift serum testosterone concentration to the desired range in those who do not achieve this range with this dose.
引用
收藏
页码:789 / 795
页数:7
相关论文
共 50 条
  • [1] Transdermal testosterone gel: Pharmacokinetics and efficacy of dosing and application site in hypogonadal men.
    Meikle, AW
    Matthias, D
    Hoffman, A
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2003, 51 : S148 - S148
  • [2] Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men
    Swerdloff, RS
    Wang, C
    Cunningham, G
    Dobs, A
    Iranmanesh, A
    Matsumoto, AM
    Snyder, PJ
    Weber, T
    Longstreth, J
    Berman, N
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12): : 4500 - 4510
  • [3] Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men
    Yu, ZL
    Gupta, SK
    Hwang, SS
    Kipnes, MS
    Mooradian, AD
    Snyder, PJ
    Atkinson, LE
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (12): : 1139 - 1145
  • [4] Pharmacokinetics of transdermal testosterone gel in hypogonadal men:: Application of gel at one site versus four sites:: A general clinical research center study
    Wang, C
    Berman, N
    Longrstreth, JA
    Chuapoco, B
    Hull, L
    Steiner, B
    Faulkner, S
    Dudley, RE
    Swerdloff, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03): : 964 - 969
  • [5] Transdermal testosterone gel increase the serum testosterone level in hypogonadal men
    Wu, C. C.
    Chiang, H. S.
    Hwang, T. I. S.
    [J]. INTERNATIONAL JOURNAL OF ANDROLOGY, 2005, 28 : 61 - 61
  • [6] Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men
    Mazer, N
    Bell, D
    Wu, JY
    Fischer, J
    Cosgrove, M
    Eilers, B
    [J]. JOURNAL OF SEXUAL MEDICINE, 2005, 2 (02): : 213 - 226
  • [7] Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: Influence of dose
    Brocks, DR
    Meikle, AW
    Boike, SC
    Mazer, NA
    Zariffa, N
    Audet, PR
    Jorkasky, DK
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (08): : 732 - 739
  • [8] TRANSDERMAL TESTOSTERONE TREATMENT OF HYPOGONADAL MEN
    CAREY, PO
    HOWARDS, SS
    VANCE, ML
    [J]. JOURNAL OF UROLOGY, 1988, 140 (01): : 76 - 79
  • [9] Transdermal testosterone administration in hypogonadal men: Comparison of pharmacokinetics at different sites of application and at the first and fifth days of application
    Yu, ZL
    Gupta, SK
    Hwang, SS
    Cook, DM
    Duckett, MJ
    Atkinson, LE
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (12): : 1129 - 1138
  • [10] EFFICACY AND PHARMACOKINETICS OF ORAL TESTOSTERONE (LPCN 1021) IN HYPOGONADAL MEN
    Chidambaram, N.
    Goldstein, I
    Dobs, A. S.
    Kaminetsky, J. C.
    Miner, M. M.
    Khera, M.
    Delconte, A.
    Chidambaram, N.
    Nachaegari, S.
    Patel, M.
    Wang, C.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2016, 13 (05): : S14 - S14